Biocon is planning to launch the skin disease drug under the brand — Alzumab — in India during the second quarter of 2013.
The drug is used in the treatment of moderate to severe psoriasis, which is estimated to have a market size of over $8 billion by 2016 globally.
The company intends to manufacture and formulate the product as an infusion drug at its biopharma manufacturing facility at Biocon Park in Bangalore.
“We expect it (Alzumab) to be a Rs 100 crore product in the next four years,” Shaw said.
The company was targeting revenue of over Rs 100 crore from its skin disease drug over the next four years.
Meanwhile, Shaw wasn’t in favour of compulsory licensing. Drugs brought under the compulsory licence perview will have a significant price difference to that of multi-national brands and is an attempt by the government to make products affordable to common man.
Post a Comment